This study is currently not recruiting participants.

Kallikrein related peptidase 2 (KLK2) testing in patients with renal cell carcinoma

Investigating a Specific Protein Called KLK2 as a Marker for Disease Progression and Therapy Resistance

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The objective of this study is to determine whether an androgen receptor induced protein such as KLK2 can be a marker of disease progression and resistance to therapies.

Detailed description of study

The objective of this study is to determine whether an androgen receptor induced protein such as KLK2 can be a marker of disease progression and resistance to therapies.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: renal cell carcinoma,kidney cancer
  • Age: 100 years or below
  • Gender: All

This study investigates whether a protein called KLK2, which is induced by androgen receptors, can be used as a marker for disease progression and resistance to treatments. Androgens are male hormones, and their receptors are proteins in the body that bind to these hormones. KLK2 is a protein that may provide important information about how a disease progresses.

Participants in this study will undergo procedures to measure levels of KLK2 and observe changes over time. This will help researchers understand if KLK2 can reliably indicate disease progression or resistance to therapies.

  • Who can participate: Eligibility criteria include specific age ranges and health conditions related to the study focus, although detailed criteria are not specified here.
  • Study details: Participants will have their KLK2 levels measured and monitored to assess changes related to disease progression and treatment resistance.
Updated on 19 Feb 2024. Study ID: 1806943858

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team